KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Capital Expenditures (2018 - 2024)

Historic Capital Expenditures for Esperion Therapeutics (ESPR) over the last 4 years, with Q3 2024 value amounting to $150000.0.

  • Esperion Therapeutics' Capital Expenditures changed N/A to $150000.0 in Q3 2024 from the same period last year, while for Jun 2025 it was $150000.0, marking a year-over-year decrease of 1017.96%. This contributed to the annual value of $317000.0 for FY2024, which is N/A changed from last year.
  • Per Esperion Therapeutics' latest filing, its Capital Expenditures stood at $150000.0 for Q3 2024.
  • In the past 5 years, Esperion Therapeutics' Capital Expenditures ranged from a high of $408000.0 in Q1 2020 and a low of -$83000.0 during Q3 2020